ClinicalTrials.gg
CompletedNCT06104306Updated Feb 11, 2026Results posted

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

A Phase 4 interventional study of B/F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Completed at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to learn how safe it is to switch to an oral therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) from Cabotegravir + Rilpivirine (CAB+RPV) in participants living with virologically suppressed human immunodeficiency virus type 1 (HIV-1), meaning participants with HIV RNA levels below detectable levels.

The primary objective of this study is to assess the safety of switching to B/F/TAF in virologically suppressed participants unable/unwilling to continue on CAB+RPV intramuscular (IM) injections or wishing to switch to oral therapy through Week 12.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • People with type 1 (HIV-1) (PWH) or provider decision to switch off cabotegravir + rilpivirine (CAB+RPV) intramuscular (IM) injections due to intolerance, inconvenience, adverse events (AEs), or willing to switch to (and intention to remain on) daily bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).
  • Currently virologically suppressed (HIV-1 ribonucleic acid (RNA) \< 50 copies/mL) on CAB+RPV IM injections every 2 months.
  • Currently on CAB+RPV IM injections every 2 months and received at least one dose of CAB+RPV IM injection; no missed CAB+RPV injections.
  • Ability to receive B/F/TAF up to 7 days prior to the next scheduled dose of CAB+RPV.
  • Documented plasma HIV-1 RNA \< 50 copies/mL during treatment for ≥ 6 months preceding the screening visit.
  • No documented or suspected resistance to bictegravir, emtricitabine, or tenofovir.

Key Exclusion Criteria:

  • History of B/F/TAF intolerance.
  • History of previous integrase strand-transfer inhibitor (INSTI) virologic failure including CAB+RPV.
  • Requirement for ongoing therapy with any prohibited medications listed in local prescribing information for B/F/TAF starting within 30 days prior to screening until 30 days following the last dose of study drug.
  • Have been treated within 3 months of study screening or expected to receive during the study therapies or chemotherapeutic agents (eg, chronic (at least 4 weeks) systemic , immunoglobulins, and other immune- or cytokine-based therapies)
  • Need for oral antiretroviral therapy (ART) bridge or use of other antiretroviral (ARV) agents prior to starting B/F/TAF on Day 1

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    B/F/TAF

    Participants will receive a fixed dose combination of B/F/TAF 50/200/25 mg once daily for 24 weeks.

    Drug: B/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint)

    Treatment emergent adverse events (TEAEs) were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days or any AE leading to study drug discontinuation. The severity of AEs were be graded using the Division of AIDS (DAIDS) Toxicity Grading Scale. The DAIDS grading table provide an adverse events (AE) severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death

    Time frame: Week 12

  2. Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 12 (Co-Primary Endpoint)

    Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any time after baseline up to and including the date of last dose of study drug plus 30 days. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening.

    Time frame: Week 12

Secondary outcomes

  1. Plasma Concentrations of Cabotegravir (CAB), and Rilpivirine (RPV) at Day 1 (Predose)

    Time frame: Day 1 (Predose)

  2. Plasma Concentration of Bictegravir (BIC), CAB, and RPV at Week 4

    Time frame: Week 4 (at trough and 2 hours postdose)

  3. Plasma Concentration of BIC, CAB, and RPV at Week 12

    Time frame: Week 12 (at trough and 2 hours postdose)

  4. Plasma Concentration of BIC, CAB, and RPV at Week 24

    Time frame: Week 24 (at trough and 2 hours postdose)

  5. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Missing = Excluded Approach

    This outcome measure analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data were excluded in the analysis.

    Time frame: Week 12

  6. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Missing = Excluded Approach

    This outcome measure analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data were excluded in the analysis.

    Time frame: Week 24

  7. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Discontinuation = Failure Approach

    This outcome measure was analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation were treated as HIV-1 RNA \>= 50 copies/mL (failure) in the analysis.

    Time frame: Week 12

  8. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Discontinuation = Failure Approach

    This outcome measure was analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation were treated as HIV-1 RNA \>= 50 copies/mL (failure) in the analysis.

    Time frame: Week 24

  9. Percentage of Participants With Discontinuation of B/F/TAF by Week 12

    Time frame: Up to 12 Weeks

  10. Percentage of Participants With Discontinuation of B/F/TAF by Week 24

    Time frame: Up to 24 Weeks

  11. Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 24

    Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any time after baseline up to and including the date of last dose of study drug plus 30 days. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening.

    Time frame: Week 24

  12. HIV Treatment Satisfaction (HIVTSQc) Score at Week 4

    The HIVTSQc was a 1-12 items questionnaire. Each item was scored -3 to 3. The total score ranged from -33 to +33, based on 11 items. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 represented no change.

    Time frame: Week 4

07

Results

Posted Feb 11, 2026

Participant flow

Participants were enrolled at study sites in the United States, France, and Canada.

Participant flow — Overall Study
MilestoneBictegravir/Emtricitabine/Tenofovir (B/F/TAF)
Started33
Completed29
Not completed4
Withdrew: Lost to follow-up2
Withdrew: Death1
Withdrew: Withdrew consent1

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint)

Treatment emergent adverse events (TEAEs) were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days or any AE leading to study drug discontinuation. The severity of AEs were be graded using the Division of AIDS (DAIDS) Toxicity Grading Scale. The DAIDS grading table provide an adverse events (AE) severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint)
percentage of participantsB/F/TAF
Percentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint)0
PrimaryPercentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 12 (Co-Primary Endpoint)

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any time after baseline up to and including the date of last dose of study drug plus 30 days. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 12 (Co-Primary Endpoint)
percentage of participantsB/F/TAF
Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 12 (Co-Primary Endpoint)3.1
SecondaryPlasma Concentrations of Cabotegravir (CAB), and Rilpivirine (RPV) at Day 1 (Predose)
Time frame:
Day 1 (Predose)
Reported as:
Mean · ng/mL
Plasma Concentrations of Cabotegravir (CAB), and Rilpivirine (RPV) at Day 1 (Predose)
ng/mLB/F/TAF
CAB1650 ± 1010
RPV68.3 ± 26.1
SecondaryPlasma Concentration of Bictegravir (BIC), CAB, and RPV at Week 4
Time frame:
Week 4 (at trough and 2 hours postdose)
Reported as:
Mean · ng/mL
Plasma Concentration of Bictegravir (BIC), CAB, and RPV at Week 4
ng/mLB/F/TAF
BIC, Trough3590 ± 2030
BIC, 2 Hours Postdose6350 ± 2210
CAB, Trough929 ± 739
CAB, 2 Hours Postdose975 ± 761
RPV, Trough57.8 ± 20.8
RPV, 2 Hours Postdose55.7 ± 21.1
SecondaryPlasma Concentration of BIC, CAB, and RPV at Week 12
Time frame:
Week 12 (at trough and 2 hours postdose)
Reported as:
Mean · ng/mL
Plasma Concentration of BIC, CAB, and RPV at Week 12
ng/mLB/F/TAF
BIC, Trough3850 ± 2550
BIC, 2 Hours Postdose6550 ± 2100
CAB, Trough667 ± 982
CAB, 2 Hours Postdose647 ± 873
RPV, Trough47.2 ± 22.4
RPV, 2 Hours Postdose45.4 ± 22.4
SecondaryPlasma Concentration of BIC, CAB, and RPV at Week 24
Time frame:
Week 24 (at trough and 2 hours postdose)
Reported as:
Mean · ng/mL
Plasma Concentration of BIC, CAB, and RPV at Week 24
ng/mLB/F/TAF
BIC, Trough2820 ± 1530
BIC, 2 Hours Postdose6410 ± 1340
CAB, TroughNA ± NA
CAB, 2 Hours PostdoseNA ± NA
RPV, Trough37.1 ± 22.3
RPV, 2 Hours Postdose33.1 ± 17.4
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Missing = Excluded Approach

This outcome measure analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data were excluded in the analysis.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Missing = Excluded Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Missing = Excluded Approach0.0 (0.0 to 11.6)
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Missing = Excluded Approach

This outcome measure analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data were excluded in the analysis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Missing = Excluded Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Missing = Excluded Approach0.0 (0.0 to 11.9)
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Discontinuation = Failure Approach

This outcome measure was analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation were treated as HIV-1 RNA \>= 50 copies/mL (failure) in the analysis.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Discontinuation = Failure Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Discontinuation = Failure Approach3.2 (0.1 to 16.7)
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Discontinuation = Failure Approach

This outcome measure was analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation were treated as HIV-1 RNA \>= 50 copies/mL (failure) in the analysis.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Discontinuation = Failure Approach
percentage of participantsB/F/TAF
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Discontinuation = Failure Approach9.4 (2.0 to 25.0)
SecondaryPercentage of Participants With Discontinuation of B/F/TAF by Week 12
Time frame:
Up to 12 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Discontinuation of B/F/TAF by Week 12
percentage of participantsB/F/TAF
Percentage of Participants With Discontinuation of B/F/TAF by Week 123.0 (0.1 to 15.8)
SecondaryPercentage of Participants With Discontinuation of B/F/TAF by Week 24
Time frame:
Up to 24 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Discontinuation of B/F/TAF by Week 24
percentage of participantsB/F/TAF
Percentage of Participants With Discontinuation of B/F/TAF by Week 249.1 (1.9 to 24.3)
SecondaryPercentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 24

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any time after baseline up to and including the date of last dose of study drug plus 30 days. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 24
percentage of participantsB/F/TAF
Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 246.3
SecondaryHIV Treatment Satisfaction (HIVTSQc) Score at Week 4

The HIVTSQc was a 1-12 items questionnaire. Each item was scored -3 to 3. The total score ranged from -33 to +33, based on 11 items. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 represented no change.

Time frame:
Week 4
Reported as:
Mean · score on scale
HIV Treatment Satisfaction (HIVTSQc) Score at Week 4
score on scaleB/F/TAF
HIV Treatment Satisfaction (HIVTSQc) Score at Week 427 ± 9.0

Adverse events

Collected over All-cause mortality: Up to 25 weeks; Adverse events: Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B/F/TAF1/33 (3%)2/33 (6.1%)10/33 (30.3%)
Most frequent serious events
Most frequent serious events
EventB/F/TAF
Abdominal pain upperGastrointestinal disorders1/33
Diverticulum intestinalGastrointestinal disorders1/33
Gastrointestinal haemorrhageGastrointestinal disorders1/33
Road traffic accidentInjury, poisoning and procedural complications1/33
Most frequent other events
Most frequent other events
EventB/F/TAF
DiarrhoeaGastrointestinal disorders4/33
NauseaGastrointestinal disorders2/33
VomitingGastrointestinal disorders2/33
Upper respiratory tract infectionInfections and infestations2/33
Back painMusculoskeletal and connective tissue disorders2/33
Neck painMusculoskeletal and connective tissue disorders2/33
DizzinessNervous system disorders2/33
HeadacheNervous system disorders2/33

Baseline characteristics

The Safety Analysis Set included all enrolled participants who have received at least 1 dose of the study drug (B/F/TAF).

Age, Categorical
Age, Categorical(Participants)B/F/TAF
<=18 years0
Between 18 and 65 years28
>=65 years5
Age, Continuous
Age, Continuous(years)B/F/TAF
Mean47 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)B/F/TAF
Female9
Male24
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAF
Race — White18
Race — Black or African American6
Race — Not Collected4
Race — Other or More Than One Race2
Race — American Indian or Alaska Native1
Race — Asian1
Race — Native Hawaiian or Other Pacific Islander1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAF
Ethnicity — Not Hispanic or Latino20
Ethnicity — Hispanic or Latino11
Ethnicity — Not Collected2
Region of Enrollment
Region of Enrollment(Participants)B/F/TAF
United States27
France4
Canada2
08

Study locations

18 sites
  • Franco Felizarta, MD
    Bakersfield, California 93301, United States
  • BIOS Clinical Research
    Palm Springs, California 92262, United States
  • UC San Diego AntiViral Research Center (AVRC)
    San Diego, California 92103, United States
  • Midway Immunology and Research Center
    Ft. Pierce, Florida 34982, United States
  • Bliss Health
    Orlando, Florida 32806, United States
  • Indiana University Infectious Diseases Research
    Indianapolis, Indiana 46202, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Las Vegas Research Center
    Las Vegas, Nevada 89106, United States
  • Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
  • MultiCare Rockwood Main Clinic
    Spokane, Washington 99202, United States
  • Hamilton Health Sciences-SIS Clinic
    Hamilton, L8L2X2, Canada
  • St. Michael's Hospital
    Toronto, M5B 1W8, Canada
  • University Health Network - Toronto General Hospital
    Toronto, M5G 2C4, Canada
  • CHU Bordeaux - Hopital Saint-Andre
    Bordeaux, 33075, France
  • APHM - Hospital Sainte Marguerite
    Marseille, France
  • CHR Orleans
    Orléans, 45100, France
  • Centre Hospitalier Annecy Genevois
    Pringy, 74374, France
  • HU de Strasbourg - Nouvel Hopital Civil
    Strasbourg, France
09

References and documents

Publications

  • Priyanka Arora, Moti Ramgopal, Thomas CS Martin, Hui Liu, Jason T Hindman, Jason Okulicz, Dhananjay D Marathe, Samir Gupta Pharmacokinetics and Safety Data After Switching From Injectable CAB + RPV to Oral B/F/TAF 20th European AIDS Conference (EACS); October 15-18, 2025
  • Samir Gupta, Thomas Martin, Cyril Gaultier, Alexandra Kissling, Kathleen Beusterien, Megan Chen, Megan Dunbar, Hui Liu, Brenda Ng, Moti Ramgopal Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to B/F/TAF From CAB + RPV: Results From the Phase 4 EMPOWER Study IDWeek; October 19-22, 2025; Atlanta, GA, USA
  • Sharon Walmsley, Moti Ramgopal, Thomas Martin, Jason T Hindman, Hui Liu, Keith Aizen, Jason Okulicz, Samir Gupta A Phase 4 Study to Evaluate the Safety and Efficacy of Oral B/F/TAF After Discontinuing Injectable CAB + RPV IDWeek; October 19-22, 2025; Atlanta, GA, USA

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jan 2025, 13 months.

Results were first posted in Feb 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Dec 13, 2023
Primary completionActual
Jan 29, 2025
CompletionActual
Apr 23, 2025
Results first posted
Feb 11, 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06104306
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Dec 13, 2023
Primary completion
Jan 29, 2025
Completion
Apr 23, 2025
Results posted
Feb 11, 2026
Last update
Feb 11, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion